O câncer de mama corresponde a aproximadamente um quarto das neoplasias malignas em mulheres. A incidência do câncer de mama no Brasil é de cerca de 50.000 novos casos por ano, sendo considerado importante problema de saúde pública. HER2 e receptores hormonais (receptores de estrógeno e progesterona) são considerados os mais importantes marcadores prognósticos e preditivos em carcinoma de mama. A amplificação do gene HER2 ou a superexpressão da proteína HER2, que ocorre em cerca de 20 porcento dos carcinomas de mama, está associada a curso clínico mais agressivo e determina elegibilidade para terapia específica anti-HER2 com trastuzumabe. A terapia hormonal reduz em mais de 50 porcento o risco relativo de recorrência da doença em pacientes com tumores sensíveis a esse tratamento. Os testes de HER2 e receptores hormonais são partes essenciais da avaliação clínica das pacientes com carcinoma de mama; resultados precisos são fundamentais na identificação de pacientes que podem ser beneficiadas por terapias específicas. O presente estudo investigou a concordância nos resultados dos testes de HER2 e receptores hormonais determinados por imuno-histoquímica em 500 carcinomas invasivos de mama entre um laboratório referência e laboratórios locais de todas as regiões geográficas do Brasil. Os resultados demonstram baixa concordância geral (171/500 casos, 34,2 porcento) em relação aos resultados do teste de HER2 entre laboratórios locais e referência, o que pode estar relacionado ao baixo volume de testes de HER2 realizados, inexperiência com o sistema de escores de HER2 e/ou questões técnicas relacionadas à imuno-histoquímica nos laboratórios locais. A concordância nos resultados do teste de receptores de estrógeno e progesterona foi de 89,4 porcento (447/500 casos) e de 85,0 porcento (425/500 casos), respectivamente, entre laboratórios locais e referência. Padronização dos testes de HER2 e receptores hormonais com medidas de controle de qualidade rigorosas por laboratórios locais é fortemente recomendada para se evitar o tratamento inadequado de pacientes com câncer de mama / Breast cancer accounts for approximately one quarter of all cancers in females. The incidence of breast cancer in Brazil is about 50,000 new cases per year, and it is considered an important public health problem. HER2 and hormone receptors (estrogen and progesterone receptors) are considered the main prognostic and predictive markers for breast carcinoma. HER2 gene amplification or HER2 protein overexpression, detected in about 20 percent of breast carcinomas, predicts a more aggressive clinical course and determines eligibility for targeted therapy with trastuzumab. Hormonal therapy reduces the relative risk of recurrence by more than 50% in breast cancer patients with hormone-sensitive tumors. HER2 and hormone receptors testing has become an essential part of the clinical evaluation of all breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from targeted therapy. The present study investigated the concordance in the results of HER2 and hormone receptors immunohistochemistry assays performed in 500 invasive breast carcinomas between a reference laboratory and local laboratories from all geographic regions of Brazil. Our results showed an overall poor concordance (171/500 cases, 34.2 percent) regarding HER2 results between local and reference laboratories, which may be related to the low-volume load of HER2 assays, inexperience with HER2 scoring system, and/or technical issues related to immunohistochemistry in local laboratories. The concordance of estrogen and progesterone receptors results was 89.4 percent (447/500 cases) and 85.0 percent (425/500 cases), respectively, between local and reference laboratories. Standardization of HER2 and hormone receptors testing with rigorous quality control measures by local laboratories is highly recommended in order to avoid erroneous treatment of breast cancer patients

Purpose: to evaluate if there is a difference between adjuvant chemo-endocrine therapy (QHT) and hormone therapy (HT) alone in ten years overall survival (OS) in post-menopausal women with early stage luminal A breast cancer Methods: A non concurrent cohort study was conducted in a cancer treatment center in Peru, we measured demographic and clinical-pathologic anatomy variables. Log-rank test and a Kaplan-Meier (KM) curve were performed to evaluate ten years OS. Cox regression analysis was used and hazard ratio were reported with confidence intervals 95% (95%CI) for crude and adjusted by the significant variables in the bivariate analysis. The fullfilment of hazard proportionality was evaluated by Schoenfeld residuals method and graphic method. Results: 65 patients received adjuvant chemo-endocrine therapy and 140 only received hormone therapy. Ten years OS was 77% for QHT and 84% for HT, this difference was not significant when using KM and log-rank; age at diagnosis (p=0,01), clinical status (p=0,02), tumor size (p=0,04), positive estrogen receptor (p=0,03), node status (p=0,012) and type of surgery (p=0,03) were statistically significant when compare with OS. When proportional hazards assumption was evaluated (SPH), only the period of time after two years of following was satisfied, cox models were created for this period of time. Crude HR for ten years OS was 1,48 (CI95%:0,65-3,39). First model adjusted HR was 1,83 (CI95%:0,64-5,30) and second model adjusted HR was 1,77 (CI95%:0,64-4,90). Conclusions: There was no significant difference in ten years OS between both courses of treatment evaluated in post-menopausal women with luminal A breast cancer. / Objetivo: evaluar si existe diferencia en la supervivencia global (SG) a diez años entre la quimioterapia adyuvante asociada a hormonoterapia (QHT) frente a la hormonoterapia sola en mujeres posmenopáusicas diagnosticadas con cáncer de mama luminal A (CMLA) en estadio temprano. Métodos: se realizó un estudio cohortes no concurrente en un centro de atención oncológica en Perú. Se incluyeron variables demográficas y clínico-patológicas. Para comparar la SG se utilizó la curva de Kaplan-Meier (KM), test de log-Rank y la regresión de Cox para estimar el Hazard Ratio (HR) con intervalos de confianza 95% (IC95%) tanto crudos como ajustados por las variables asociadas durante el análisis bivariado. Se evaluó el cumplimiento del supuesto de proporcionalidad de hazard (SPH) con el método de residuos de Schoenfeld y método gráfico. Resultados: 65 pacientes recibieron QHT y 140 sólo hormonoterapia. La SG a los diez años fue 77% y 84% para QHT y HT respectivamente, esta diferencia no fue significativa al utilizar KM y test de log-Rank; no obstante la edad (p=0,01), estadio clínico (p=0,02), tamaño tumoral (p=0,04), receptor estrogénico positivo (p=0,03), número de ganglios (p=0,012) y tipo de cirugía (p=0,03) resultaron asociadas significativamente a la supervivencia global a los diez años. Cuando se evaluó el SPH se evidenció que sólo se cumplía tras los dos años de seguimiento, por lo que se generaron modelos de Cox en éste periodo. El HR crudo a los diez años fue de 1,48 (IC95%: 0,65-3,39). En el modelo ajustado uno se observó un HR de 1,83 (IC95%: 0,64-5,30) y para el segundo modelo ajustado un HR de 1,77 (IC 95%: 0,64-4,90). Conclusiones: no se encontró diferencia significativa en la SG a los diez años entre los esquemas terapéuticos evaluados en mujeres posmenopáusicas con CMLA.

Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-01-11T12:24:30Z No. of bitstreams: 1 patriciaoliveiracarmo.pdf: 901114 bytes, checksum: 4238f828115db8965f8df71f43a82da1 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-01-25T17:05:15Z (GMT) No. of bitstreams: 1 patriciaoliveiracarmo.pdf: 901114 bytes, checksum: 4238f828115db8965f8df71f43a82da1 (MD5) / Made available in DSpace on 2016-01-25T17:05:15Z (GMT). No. of bitstreams: 1 patriciaoliveiracarmo.pdf: 901114 bytes, checksum: 4238f828115db8965f8df71f43a82da1 (MD5) Previous issue date: 2015-06-19 / Em geral, o câncer de mama subtipo luminal exibe melhor prognóstico em relação aos outros subtipos tumorais. No entanto, a doença nesta condição pode assumir uma evolução desfavorável em algumas circunstâncias, o que sinaliza para a necessidade de melhor entendimento sobre o comportamento deste subtipo tumoral. O presente estudo teve por objetivo estimar a sobrevida livre de doença de mulheres em cinco anos com câncer de mama subtipo luminal e avaliar as variáveis prognósticas, clínicas, sociodemográficas, histopatológicas, relacionadas à utilização dos serviços de saúde e ao tratamento visando conhecer o impacto destas e sua implicação na recorrência e sobrevida da população estudada. Os dados foram obtidos a partir de uma coorte de base hospitalar, composta por 331 mulheres diagnosticadas com a doença no período entre 2003 e 2005, com perfil imunohistoquímico compatível com tumor luminal, não metastático (estadios I, II e III), atendidas em hospital referência em Oncologia no Município de Juiz de Fora – MG. A sobrevida livre de doença em cinco anos foi de 79,5% (IC95%: 74,6-83,6). Na análise univariada, observou-se associação da recorrência do tumor com o tipo de serviço de saúde, estadiamento, tamanho tumoral, comprometimento linfonodal e número de linfonodos comprometidos, quimioterapia e hormonioterapia (p<0,05), sendo verificada menor recorrência para as mulheres que frequentaram o serviço privado, que apresentaram doença inicial, menor tamanho tumoral e ausência de comprometimento linfonodal axilar e que foram submetidas a hormonioterapia. No modelo multivariado, permaneceram gravidade da doença e hormonioterapia como os fatores prognósticos mais importantes. As técnicas de biologia molecular representam o futuro do tratamento do câncer e também para os tumores luminais. Deve-se garantir o acesso ao tratamento hormonal quando indicado e os estágios avançados devem ser objeto de abordagem terapêutica mais ampliada. / Luminal breast cancer usually has a better prognosis in relation to other tumoral subtypes. Nonetheless, the illness in this point can evolve unfavorably in some circumstances what signals the need for a better understanding about this tumoral subtype behavior. The present study aimed at estimating the diseasefree survival of women with luminal breast cancer in five years. In this study, many variables have been evaluated, including prognostic, clinic, sociodemographic, histopathological and related to the use of public health services and treatment, aiming to get to know their impact and implications on recurrence and survival among the population of the study. The database was a hospital based cohort study, composed of 331 women diagnosed with the disease between 2003 and 2005, with immunohistochemical profile compatible with luminal breast cancer, non-metastatic (stages I, II or III), treated in a hospital seen as a reference for cancer care in Juiz de Fora, MG. The study showed a disease-free survival of 79.5% (IC95%: 74.6-83.6) in five years. The univariate analysis has shown an association of tumor recurrence with the type of health care, staging, tumor size, lymph node involvement and their number, chemotherapy and hormonal therapy (p<0.05) and it has indicated better survival rates among women who used private health care, who are in an initial stage, with smaller tumors, no axillary involvement and who used hormonal therapy. In the multivariate model, there remained gravity of the illness and the use of hormonal therapy as the most important prognostic factors. Molecular biology techniques represent the future for cancer treatment and also for luminal tumors. Access to hormonal therapy should be granted whenever prescribed and advanced stages must receive an amplified range of therapeutic approach.

Made available in DSpace on 2016-07-18T17:53:16Z (GMT). No. of bitstreams: 1 ronaldo sena e silva.pdf: 758805 bytes, checksum: 50ddd870dfedb208e155053c6ec67166 (MD5) Previous issue date: 2015-09-24 / The aim of this study was to verify the use of growth hormone (GH), with or without resisted exercise, the estrous cycle, the dosage of the estradiol and progesterone and Wistar rats endometrium thickness. The rats were divided into four groups (n = 10): CT (Control); Ex (resisted exercise - water jumps with 50% of body weight); GH (0,2UI / kg administered GH); and ExGH (GH and Ex groups combined treatment). The estrous cycle phase of rats were determined by vaginal cytology, daily for 29 days. The rats plasma was used for hormone dosage and the endometrium thicknesses were evaluated by histology. We used the Shapiro-Wilk normality presupposition. For samples that was parametric, ANOVA was used with Tukey, for no parametric samples, Kruskal-Wallis with Student-Newman-Keuls test was used (p<0.05). There are a greater reproductive cycles number in CT than in other groups during the 29 days period (p>0.05), no difference were found between the hormones dosage groups neither endometrial thickness. Therefore, it is concluded that GH and resisted exercises both combined affect females reproductive cycle, they reduced the number of cycles of rats but they do not change the estradiol and progesterone concentrations, neither endometrial thickness. / O objetivo deste estudo foi verificar o uso do hormônio do crescimento (GH), associado ou não ao exercício resistido, no ciclo estral, na dosagem do estradiol e progesterona e na espessura do endométrio de ratas Wistar. As ratas foram divididas em 4 grupos (n=10): CT (controle); Ex (exercício resistido - saltos em água com 50% do peso corporal); GH (0,2UI/Kg de GH administrado); e ExGH (tratamento combinado dos grupos GH e Ex). A fase do ciclo estral foi determinada por citologias vaginais nas ratas, diariamente, durante 29 dias. Foi realizado dosagem hormonal nas ratas e as espessuras dos endométrios foram avaliadas por histologia. Utilizou-se o pressuposto de normalidade de Shapiro-Wilk. Para as amostras paramétricas, utilizou-se ANOVA e Tukey e para não paramétricas Kruskal-Wallis e Student-Newman-Keuls (p<0,05). Houve maior número de ciclos reprodutivos no CT que nos demais grupos no período de 29 dias (p<0,05), nenhuma diferença foi encontrada entre os grupos na dosagem hormonal ou na espessura de endométrio. Portanto, conclui-se que o GH, o exercício resistido e os dois combinados interferem na ciclicidade reprodutiva das fêmeas, reduzindo o número de ciclos das ratas, sem alterar a concentração de estradiol e progesterona ou a espessura do endométrio.

<p>Funkcija nosa povezana je sa različitim anatomskim, fiziolo&scaron;kim i emocionalnim faktorima. Postoji mnogo teorija koje su poku&scaron;ale da objasne efekat ženskih polnih hormona (estrogena i progesterona) na fiziologiju nosa, ali sam mehanizam njihovog dejstva jo&scaron; uvek ostaje izazov za mnoge istraživače. Prethodno je opisano da ženski polni hormoni mogu da izazovu nazalnu opstrukciju, povećavajući ekspresiju histaminskih H1 receptora i menjajući koncentraciju neurotransmitera, &scaron;to dovodi do edema nosne sluznice i modifikacije nazalnog otpora. Kada je reč o mirisnoj funkciji na malom broju ispitanika i u različito dizajniranim studijama je pokazano da je u fazi ovulacije mirisni prag značajno niži u odnosu na folikularnu i luteinsku fazu, međutim ne postoje podaci o identifikaciji i diskriminaciji mirisa u menstrualnom ciklusu. Nizak nivo estrogena prouzrokovan fiziolo&scaron;kom atrofijom jajnika u postmenopauzi može dovesti do hiposmije ili čak anosmije, &scaron;to predstavlja jo&scaron; jedan dokaz o osetljivosti nazalne sluznice na estrogen.&nbsp; Cilj ovog istraživanja je bio da se ispita uticaj ženskih polnih hormona na respiratornu i mirisnu funkciju nosa u menstrualnom ciklusu i postmenopauzi. Istraživanje je u celosti prospektivno, sprovedeno je na Zavodu za fiziologiju, Medicinskog fakulteta, Univerziteta u Novom Sadu. Uključeno je 204 osoba ženskog pola koje su bile podeljene u dve grupe. Prvu grupu su činile 103 devojke uzrasta 23,126 &plusmn; 4,597 godina u reproduktivnom periodu sa regularnim menstrualnim ciklusom i 101 žena prosečnog uzrasta 60,069 &plusmn; 5,570 u postmenopauzi. Respiratorna i mirisna funkcija nosa procenjene su uz pomoć odgovarajućih standaradizovanih objektivnih i subjektivnih metoda. Funkcija donjih disajnih puteva ispitana je uz pomoć spirometrije. Kod žena u reproduktivnom periodu testiranje se vr&scaron;ilo u fazi ovulacije i lutealnoj fazi menstrualnog ciklusa, a kod ispitanica u postmenopauzi jednom. Nakon određivanja prvog plodnog dana ispitanice su uz pomoć standardizovanih urin - tračica za određivanje pika luteinizirajućeg hormona u urinu utvrđivale momenat ovulacije, dok se drugo testiranje u lutealnoj fazi vr&scaron;ilo sedam dana nakon prvog. Respiratorna funkcija nosa je značajno lo&scaron;ija u fazi ovulacije u odnosu na progesteronsku fazu menstrualnog ciklusa,ali se značajno ne razlikuje između žena u reproduktivnom periodu i žena u postmenopauzi. Subjektivni osećaj nazalne opstrukcije značajno se ne razlikuje u različitim fazama menstrualnog ciklusa, kao ni između testiranih populacija zdravih žena. Sposobnost identifikacije mirisa je statistički značajno slabija, a subjektivni osećaj intenziteta mirisa izraženiji u fazi ovulacije u odnosu na luteinsku fazu menstrualnog ciklusa. Međutim, sposobnost identifikacije mirisa značajno je lo&scaron;ija kod žena u postmenopauzi u odnosu na obe faze menstrualnog ciklusa. Reaktivnost nosne sluznice značajno je veća u fazi ovulacije u odnosu na lutealnu fazu menstrualnog ciklusa, ali se ista ne razlikuje između žena u reproduktivnom period i žena u postmenopauzi. Respiratorna i mirisna funkcije nosa u testiranim populacijama zdravih žena nisu značajno povezane.</p> / <p>The nasal function is associated with various anatomical, physiological and emotional factors. There are many theories that have tried to explain the effect of female sex hormones (estrogen and progesterone) on the nasal physiology, but the mechanism still remains unknown for many researchers. It has been previously described that female sex hormones can cause nasal obstruction by increasing the expression of histamine H1 receptors and altering the concentration of neurotransmitters, which leads to edema of the nasal mucosa and modification of nasal resistance. When it comes to olfaction on a small number of subjects and in differently designed studies, it was shown that in the ovulatory phase the olfactory threshold is significantly lower compared to the follicular and luteal phase, however there are no data on the identification and discrimination of odors in the menstrual cycle. Low estrogen levels caused by physiological atrophy of the ovaries in postmenopause can lead to hyposmia or even anosmia, which is another proof of the sensitivity of the nasal mucosa to estrogen.&nbsp; The aim of this study was to examine the effect of female sex hormones on respiratory and olfactory function of the nose in the menstrual cycle and postmenopause. The research is prospective and it was conducted at the Department of Physiology, Faculty of Medicine, University of Novi Sad. It included 204 females who were divided into two groups. The first group consisted of 103 women aged 23.126 &plusmn; 4.597 years in the reproductive period with a regular menstrual cycle and 101 women with an average age of 60.069 &plusmn; 5.570 in the postmenopausal period. The respiratory and olfactory function of the nose were assessed using appropriate standardized objective and subjective methods. The lower airway function was examined using spirometry. Young women in reproductive period were tested twice, in the ovulatory and luteal phase of the menstrual cycle, and the postmenopausal women were tested only once. After menstrual bleeding the participans used standardized urine strips consecutively day by day to determine ovulation (the peak of the luteinizing hormone (LH) in plasma which pointed out the estrogen plasma peak). The test was positive if two horizontal pink streaks appeared on the strip 5 to 10 minutes after the contact with the urine. One pink streak indicates a correctly performed test, while the second streak appears only if there is an LH peak. Within 24 hours of confirmed LH peak, the subjects were tested for the first time. The second measurement was performed in the luteal phase of the menstrual cycle (the progesterone plasma peak) seven days after the first one.&nbsp; The nasal respiratory function is significantly worse in the ovulatory phase compared to the luteal phase of the menstrual cycle, but it does not differ significantly between women in the reproductive period and postmenopausal women. The subjective sense of the nasal obstruction does not differ significantly in different phases of the menstrual cycle, as well as between tested populations of healthy women. The odor identification ability is statistically significant weaker and the subjective sense of odor intensity is more pronounced in the ovulatory phase compared to the luteal phase of the menstrual cycle. However, the ability to identify odors is significantly worse in postmenopausal women compared to both phases of the menstrual cycle. The reactivity of the nasal mucosa is significantly higher in the ovulatory phase compared to the luteal phase of the menstrual cycle, but it does not differ between women in the reproductive period and postmenopausal women. The respiratory and olfactory nasal functions in these tested populations are not significantly corelated.</p>

Chlamydia is the most common bacterial sexually transmitted infection in the United States and worldwide. It often goes unnoticed due to lack of symptoms and left untreated it can ascend the female genital tract to cause sequelae like pelvic inflammatory disease and irreversible tubal infertility. In reproductive-aged women, female sex hormones estrogen (E2) and progesterone (P4) concentrations fluctuate during the menstrual cycle and are influenced by hormonal contraceptives and hormone replacement therapy. E2 and P4 influence genital Chlamydia infection in women and mice, but these multifactorial interactions are not entirely mapped out. The complex interplay of E2 and P4 with Chlamydia and the host response demand further study to determine the effect of hormonal environment and host susceptibility to Chlamydia. E2 primarily signals through estrogen receptors (ER) ERα and ERβ. We used ERα or ERβ knockout (KO) mice to study the role of E2 and ERs in chlamydial progression and examined the host immune response at day 9 post-infection, when we expected the immune response to be the most robust. ERαKO, but not ERβKO mice had significant differences in the progression of Chlamydia and the host immune response. Future studies should test the immune response at additional timepoints, and a model should be utilized wherein ERα and ERβ are simultaneously silenced by chemical knockdown of ERβ in ERα knockout mice using ER agonist ICI 182, 680. 3 Mice are widely used in Chlamydia research, but due to its short estrus cycle, infection cannot be established naturally before infected cells are shed. To overcome this, mice are pretreated with depot medroxyprogesterone acetate (DMPA), an exogenous progesterone that halts the estrus cycle. However, a mouse model not reliant on DMPA pretreatment is needed because 1.) DMPA can affect the immune response and 2.) the hormonal environment in women is not static. Our model uses mice that are ovariectomized to stop the production of endogenous E2 and P4, then treated with physiologically relevant levels of E2 and P4 via implantation of a hormone-filled capsule. We observed that E2 protected mice from Chlamydia, making our model a good alternative for in vivo Chlamydia studies.

La progression du cancer du sein repose principalement sur la signalisation des œstrogènes et de la progestérone, et les traitements modulant l’action des œstrogènes ont amélioré la survie des patientes atteintes d’un cancer à récepteurs œstrogéniques (ERα). Des études récentes convergent sur le concept selon lequel, dans les cancers du sein ER+, PR (Progesterone Receptor) peut inhiber les fonctions favorisant la croissance induite par l'œstrogène en reprogrammant directement la liaison d'ERα sur de nouveaux gènes cibles. Les données cliniques montrent que cette signature génique est associée à un bon pronostic dans une cohorte de 1.959 patientes atteintes de cancer du sein et qu’un agoniste de la progestérone améliore l'activité antiproliférative des thérapies anti-oestrogéniques1. Ainsi, ces données démontrent qu’ER n’est pas le seul acteur de la tumorigénèse mammaire et qu'il existe une interférence fonctionnelle entre ces deux voies hormonales, soulignant le besoin d’une meilleure compréhension de la signalisation de PR. D’un point de vue mécanistique, l’activité de PR est étroitement liée à l’interaction avec les nucléosomes. En effet, PR fonctionne comme un facteur « pionnier » et se lie à la chromatine au sein de complexes protéiques, régulant son activité transcriptionnelle. Sans progestérone, PR forme un complexe répressif associé à des enzymes modificatrices de la chromatine comme LSD1, HDAC1/2 et la protéine de l'hétérochromatine HP1γ2. En réponse au traitement hormonal, ce complexe est déplacé, ce qui permet de recruter des coactivateurs et des cofacteurs associés, qui modifient la structure de la chromatine locale et entraînent l'activation ou la répression des gènes cibles de PR. Nous avons identifié un nouveau régulateur de la signalisation de la progestérone, l'arginine méthyltransférase PRMT1, enzyme souvent surexprimée dans les cancers mammaires3,4. Par diverses approches in vitro et in vivo, nous avons montré une interaction directe entre PR et PRMT1, dans le noyau des cellules tumorales mammaires, et à la fois en absence d’hormone et après 1h de stimulation à la progestérone. De plus, PRMT1 apparaît comme un nouveau membre du complexe répressif sur la chromatine, associé à PR et à ses partenaires, dans un sous-ensemble de gènes inductibles par la progestérone. Nos résultats indiquent également que l’expression de PRMT1 affecte l’activité transcriptionnelle de PR et que son inhibition perturbe l’activation rapide de la voie de la protéine kinase après une stimulation progestative. Nous montrons pour la première fois que PR est méthylé sur un résidu arginine, conservé parmi les récepteurs nucléaires (R637), localisé dans son domaine de liaison à l'ADN. La production d’un anticorps dirigé contre la forme méthylée de PR nous a permis de préciser qu’elle se localisait dans le noyau des cellules et n’était retrouvée qu’après traitement progestatif. En outre, la mutation de R637 de PR entraine une diminution de l’expression d'un sous-ensemble de cibles de PR, ce qui entraine un retard de croissance cellulaire. En conclusion, ces résultats confirment l'implication de PRMT1 et de son activité méthyltransférase dans la signalisation de PR et plus particulièrement dans son activité transcriptionnelle. Nous démontrons donc que la méthylation sur résidus d'arginine est un nouveau mécanisme de contrôle lors de la réponse à la progestérone dans les cellules tumorales mammaires / Breast cancer progression is mainly driven by estrogen and progesterone signalling and therapies modulating oestrogen‘s action have improved the survival of ER+ cancer patients. As progesterone receptor (PR) is an ER target gene, its expression in breast cancer was considered as a predictive marker of ER functionality. However, recent studies are converging on the concept that PR can directly affect ER functions in breast cancer cells1. Activated PR can redirect ER to novel chromatin binding sites associated with cell differentiation and apoptosis, leading to a potential improvement of the tumour response to anti-oestrogen therapies. In considering the differential effects of progesterone in breast cancer, it is important to define the variable might influence progesterone pathway and the downstream mediators involved in this signalling. Recently, Beato and al reported that, in breast cancer cells, the unliganded form of PR (non-activated with progesterone) bind to genomic sites and target a repressive complex containing enzyme modifying chromatin as the demethylase LSD1 or the Heterochromatin Protein 1 (HP1γ)2. Under hormonal treatment, this complex is displaced, which makes it possible to recruit coactivators and associated cofactors, which modify the structure of the local chromatin and cause the activation or repression of the target genes of PR. In addition, cellular response to progesterone is also regulated by receptor post-translational modifications that may affect its stability, its subcellular localization and its interactions with regulators. In our study, we demonstrated for the first time that PR is methylated on arginine residues, by the arginine methyltransferase PRMT1. We identified as target the arginine 637 (R637), a conserved arginine among nuclear receptor superfamily, located in the DNA-binding domain of the receptor. By in vitro and in vivo approaches, we are studying the impact of PRMT1 on PR signalling pathways. In T47D breast cancer cells, we demonstrated that PR interacts with PRMT1, mainly in the nucleus. Of interest, PRMT1 interacts with PR in the nucleus in absence of hormone stimulation and it appears as a new member of the repressive complex on a subset of progesterone inducible genes. Our results also indicate that PRMT1 expression affects PR transcriptional activity and PRMT1 knockdown disrupts the rapid activation of protein kinase pathway after progestin stimulation. The production of an antibody directed against the methylated form of PR allowed us to specify that methylated-PR is localized in the nucleus of cells and was found only after progesterone treatment. Furthermore, PRMT1 depletion and mutation of R637 resulted in an inhibition of a subset of PR-regulated genes which led to retarded cell growth.Our data reveal the impact of PRMT1 expression on PR pathways and provide evidence for the asymmetric arginine dimethylation of PR. We therefore demonstrate that methylation on arginine residues could be a novel control mechanism in the response to progesterone in mammary tumor cells

Ziel dieser Studie war die Etablierung einer Kokultur aus equinen endometrialen Epithel- und Stromazellen. Nach der erfolgreichen Umsetzung des Kokulturmodells sollte im weiteren Versuchsablauf durch die Zugabe von 17β-Östradiol (E2) und/oder Progesteron (P4) zum Nährmedium der Einfluss der Hormone auf die Zellen untersucht werden. Neben einer lichtmikroskopischen Auswertung der zytomorphologischen Charakteristika beider Zellarten sollte die Expression der Steroidhormonrezeptoren Östrogenrezeptor α und Progesteronre-zeptor sowie der uterinen Proteine Uteroglobin und CalbindinD9k immunzytologisch überprüft werden. Für die Etablierung der Kokultur wurden Endometriumproben von lebenden (n = 5) sowie frischtoten (n = 4) Stuten gewonnen. Eine jeweils parallel entnommene Gewebeprobe von jedem Tier wurde in Formalin fixiert und diente als Referenzmaterial (in situ). Auf die Zelliso-lierung (mechanisch und enzymatisch) folgte die Separation von Epithel- und Stromazellen (EZ/SZ) mittels Filtration, Dichtegradientenzentrifugation und Differenzialadhärenz. An-schließend wurden die EZ auf die Außenseite von Millicell®-Membraneinsätzen aufgebracht. Nach zwei Tagen erfolgte das Einsäen der bis zu diesem Zeitpunkt separat kultivierten SZ auf die Innenseite der Membranen. Als Nährmedium diente ein Gemisch aus DMEM und Ham’s F-12, wobei diesem 2,5 % fötales Kälberserum sowie verschiedene Additive zugesetzt wurden. Ab Kulturtag 4 wurden dem Medium definierte Konzentrationen und Kombinationen von E2 und P4 zugesetzt. Die Kultivierung erfolgte bei einem CO2-Partialdruck von 5 % in 37 °C warmer wasserdampfgesättigter Raumluft. Mit der polarisationsmikroskopisch er-fassbaren Ausbildung durchgehender Zellrasen („scheinbare Konfluenz“) wurden die Kokul-turen in Formalin fixiert und für die Lichtmikroskopie aufgearbeitet. Das Ausgangsgewebe zeigte mehrheitlich eine sekretorische Funktionsmorphologie (n = 6). Einzelne Endometrien befanden sich in einem Übergangsstadium von der Sekretions- zur Proliferationsphase (n = 1), bzw. vice versa (n = 1) oder wiesen eine irregulär proliferative Differenzierung (n = 1) auf. Im Rahmen der Kokultivierung bildeten die EZ innerhalb der Schnittebene vier und die SZ drei verschiedene morphologische Zelltypen aus. Dabei traten rundovale bis polygonale EZ (Typ 1) selten bis gelegentlich, spindelförmige EZ (Typ 2) gelegentlich bis häufig und iso-prismatische (Typ 3) sowie mehrschichtig wachsende EZ (Typ M) jeweils selten auf. Die SZ zeigten innerhalb der Schnittebene selten eine rundovale bis polygonale Zellform (Typ 1), sehr häufig eine spindelförmige Morphologie (Typ 2) und selten ein mehrschichtiges Wachstum (Typ M). Ein Zusammenhang zwischen der endometrialen Funktionsmorphologie zum Zeitpunkt der Zellisolierung oder dem Hormonzusatz und der Häufigkeitsverteilung der Zell-typen sowie der Wachstumsgeschwindigkeit der kultivierten Zellen war nicht offensichtlich. Zytokeratin 19 wurde stets von EZ exprimiert, während es auf Seiten der SZ nur sporadisch in maximal 5 % der Zellen im Bereich mehrschichtig wachsender Zellrasen auftrat. Die Stero-idhormonrezeptoren konnten lediglich in einzelnen Kokulturen aus sekretorisch differenzier-tem Ausgangsgewebe detektiert werden. Uteroglobin wurde in vitro mit einer variablen Häufigkeit in den EZ-Typen exprimiert. Während ein übergreifender Zusammenhang zur hormonellen Supplementierung nicht abgeleitet werden konnte, wurde jedoch ersichtlich, dass im Bereich einschichtig wachsender EZ in Ansätzen aus sekretorisch differenzierten Endometrien unter niedrigen Hormondosen (Zusatz von entweder nur E2 oder nur P4) im Median häufiger Uteroglobin exprimiert wurde. Mit zunehmender Hormonkonzentration im Medium nahm der Anteil immunopositiver Zellen (Typen 1, 2 und 3) deutlich ab. Innerhalb der Stromazellpopulation wurde Uteroglobin selten und ausschließlich in Zellen aus sekretorisch differenziertem Ausgangsmaterial nachgewiesen. CalbindinD9k wurde in vitro vornehmlich intrazytoplasmatisch und sehr vereinzelt intranukleär exprimiert. Insgesamt konnte das Protein in vitro stets in wenigen Typ-1-EZ, sehr selten in Typ-2-EZ und in einer geringen bis mäßigen Anzahl von Typ-3- und Typ-M-EZ beobachtet werden. Innerhalb der Stromazellpo-pulation trat CalbindinD9k ausschließlich in einer geringen (Endometrien aus dem Östrus) bis mäßigen (Endometrien aus dem Interöstrus) Anzahl der Typ-2- und wenigen Typ-M-SZ auf. Insgesamt wurden keine deutlichen Einflüsse der endometrialen Funktionsmorphologie zum Zeitpunkt der Zellisolierung und/oder der hormonellen Supplementierung in vitro auf die im-munzytologischen Charakteristika der kokultivierten Zellen ersichtlich. Abschließend betrachtet, konnte ein Kokultursystem equiner endometrialer Epithel- und Stromazellen erfolgreich etabliert und charakterisiert werden. Es bietet dabei, trotz der z. T. fehlenden Kongruenz zu den Gegebenheiten in situ, Ansätze für potenzielle Folgearbeiten, insbesondere hinsichtlich der Erfassung interzellulärer Wechselwirkungen sowie bezüglich der Vermittlung und Wirkung hormoneller Einflüsse auf zellulärer Ebene. / The aim of the present study was the establishment of a coculture system of equine endome-trial epithelial and stromal cells. Subsequent to the successful development of the coculture model the culture medium should be supplemented with 17β-estradiol (E2) and/or progester-one (P4) in order to study the influence of the hormones on the cellular level. In addition to the examination of cytomorphological characteristics of both cell types via light microscopy, the expression of the steroid hormone receptors (estrogen receptor α and progesterone receptor) as well as of the uterine proteins Uteroglobin and CalbindinD9k was investigated. For the establishment of the coculture system endometrial samples were obtained from living (n = 5) as well as freshly deceased mares (n = 4). A simultaneously taken tissue specimen of each animal was fixed in formalin and served as in situ reference material. After an initial mechanical and enzymatical isolation the epithelial and stromal cells (EC/SC) were separat-ed via filtration, density gradient centrifugation and differential adhesion. Subsequently, the EC were applied to the outer surface of Millicell® inserts. The SC were cultivated separately for 2 days before they were seeded onto the inner surface of the same insert. The culture medium used was comprised of a DMEM and Ham‘s F-12 basis as well as 2.5 % foetal calf serum and different additives. Starting on day 4 of cultivation the standardised medium was supplemented with different concentrations and combinations of E2 and P4. Throughout the study the cultures were kept in a humidified atmosphere of 37°C and a 5 % partial pressure of carbon dioxide. Once the cocultures formed continuous cell layers, as determined via a polarisation microscope (“apparent confluency”), the membranes were fixed in formalin and routinely processed for light microscopical evaluation. The initial tissue samples predominantly showed a secretory functional morphology (n = 6), while single specimens were obtained during the transition from the secretory to the prolifera-tive phase (n = 1) or vice versa (n = 1). One endometrial sample exhibited an irregular proli-ferative differentiation. In the course of cocultivation the EC formed 4 and the SC 3 different cellular morphologies within the section plane. EC with a round-oval to polygonal cell form (type 1) were rarely to occasionally encountered, while spindle-shaped EC (type 2) were occasionally to frequently seen and EC with a cuboidal morphology (type 3) as well as such cells growing in stratified layers (type M) were only infrequently detected. The SC only rarely showed a round-oval to polygonal cell form (type 1) or areas of a stratified cell growth (type M), whereas spindle-shaped SC (type 2) were observed very often. A correlation of the endometrial functional morphology at the time of cell isolation or the hormonal supplementation and the frequency distribution of the cell types as well as the growth rate of the cultivated cells was not evident. The EC always expressed Cytokeratin 19, while on the side of the SC only up to 5 % of the cells in areas of stratified cell growth exhibited this filament. Solely in individual cocultures from secretory differentiated endometrial tissue the steroid hormone receptors could be de-tected. Uteroglobin was expressed in vitro in EC with a variable frequency. An overall corre-lation of the hormonal supplementation and the Uteroglobin expression could not be derived. However, under low hormone doses (only E2 or only P4 supplement) Uteroglobin was detect-ed in EC in areas of single-layered cell growth more often (median value). With an increase in hormone concentration the amount of immunopositive cells (types 1, 2 and 3) diminished noticeably. In SC the protein could only rarely be seen and exclusively in cells from endome-tria with a secretory functional morphology. In vitro CalbindinD9k was predominantly detected intracytoplasmatically, while single cells showed an additional intranuclear expression. Alto-gether, CalbindinD9k could always be observed in a few type-1-EC, rarely in type-2-EC and with a variable frequency in small to moderate numbers of type-3- and type-M-EC. In SC the protein was exclusively expressed in a small (endometrial samples form the oestrous phase) to moderate (endometrial tissue from the interoestrous phase) number of type-2-SC and a few type-M-SC. Generally, no distinct influence of the endometrial functional morphology at the time of tissue sampling and/or of the hormonal supplementation in vitro on the immuno-cytochemical characteristics of the cocultured cells could be observed. In summary, a coculture system of primary equine endometrial epithelial and stromal cells was successfully established and characterised. Despite of the partly absent congruence to the in situ conditions/prerequisites, the present study offers a basic approach and scaffold for further investigations, particularly regarding the ascertainment of intercellular dependencies or the mediation and effectiveness of hormonal influences on the cellular level.

Emotion, as well as cognition, are often understood as a manifestation of brain activity. However, bodily processes are also involved in mental functioning, referring to the concept of embodiment. Embodied emotion, traditionally, implies that experiencing an emotion involves perceptual, somato-visceral, and motor aspects. Within the frame of the Research Training Group “Situated Cognition”, we here extend the concept of embodiment by considering the role of hormones in the processing of emotional content. Importantly, hormones allow a bidirectional body-to-brain and brain-to-body coupling. The endocrine system, e.g., steroid sex hormones, produced in the gonads, send feedback to the brain by binding at their receptors. These receptors are relatively abundant in the brain regions associated with emotional processing, memory, and executive functions (i.e., amygdala, hippocampus, and prefrontal cortex). Moreover, peripheral hormone secretion is modulated via actions from the central nervous system. We intended to characterize the role of sex hormones, and partly also of stress hormones, on different components of emotion as a hormonal embodiment of emotion. Thus, we examined emotional processing in different sex hormone-status groups. To account for different levels of sex hormones, we used a quasi-experimental approach by comparing women in different cycle phases, women using hormonal oral contraceptives (Study 1), and additionally men (in Study 2). The female menstrual cycle is characterized by fluctuating sex hormone levels. On the peripheral gonadal level, these are 17β-estradiol and progesterone. These hormones are low at the beginning of the cycle (early follicular phase). Estradiol rises towards the middle of the cycle (mid-cycle) and stays moderately high until the next cycle. Progesterone levels are high after mid-cycle in the luteal phase until the end of the cycle. Hormonal contraceptives suppress the endogenous production of estradiol and progesterone, keeping the hormone levels low during the whole cycle. Estradiol and progesterone are also present in males, however, at low levels with no sign of cyclical fluctuations. In Study 1, we examined three independent groups of women in the mid-cycle (n = 24), in the luteal phase (n = 24), and women using hormonal oral contraceptives (n = 24). We assessed different measures of emotional processing, i. e. emotional memory, cognitive and affective empathy-related measures (emotion recognition and ratings for feeling with a protagonist´s emotion, respectively), as well as mimic and skin-conductance responses to affective stimuli. Additionally, we addressed interactions of experimental stress (cold pressor test vs. control) with sex hormones in emotional memory. Our data demonstrated the role of hormones in empathy-related measures and skin-conductance responses depending on the stimulus characteristics (valence, the gender of the protagonist). Emotional memory was not affected by hormone status, stressor or salivary hormone levels. In the cognitive empathy-related measure, women in the luteal phase, as well as oral contraceptive users, identified emotions depicted by female protagonists more accurately than those by male protagonists. On the other hand, estradiol correlated positively with recognition of emotions depicted by males in the total sample. In the affective empathy-related measure, oral contraceptive users rated negative emotions higher than the positive ones. Finally, in the luteal phase skin-conductance responses to negative stimuli were heightened, also supported by a positive correlation with the salivary progesterone levels. The mimic responses remained unaffected. None of the remaining associations with the salivary hormone levels were significant. These results indicate that sex hormones modulated emotional processing by interacting with the stimulus features, as evident in the negativity bias under oral contraceptive use and in the luteal phase in the affective empathy-related measure and sympathetic autonomous reactivity, respectively. However, emotional memory and mimic activity to affective stimuli were not affected. In Study 2, we extended the initial scope to examine the role of sex hormones and olfaction in empathy-related measures. Reports of female advantage in empathy-related measures suggest a role for sex hormones, although data are inconsistent. Studies also report similar sex differences in human olfactory perception. In rodents, olfaction is involved in detecting and integrating socially-relevant information and is modulated by the brain-actions of estrogens. Based on this background, we hypothesized that olfaction may untangle the mixed evidence regarding the relationship between sex hormones and empathy-related measures (cognitive, affective). Thus, we measured odor discrimination ability, empathy-related measures, and facial mimic activity (also associated with affective empathy-related measures) in free-cycling women in high sex-hormone phases (n = 20), oral contraceptive users (n = 19), and men (n = 21). Free-cycling women outperformed only men in the recognition of emotions depicted from the eye region. Oral contraceptive users showed higher scores in the affective empathy-related measure towards negative emotions. Free-cycling women exhibited the strongest facial mimicry (viewing female, but not male protagonists), positively associated with progesterone. Finally, the groups differed in odor discrimination, with free-cycling women outperforming men. However, odor discrimination ability and empathy-related performance were not correlated. Our results support the role of sex hormones in odor perception and empathy-related measures, to a certain extent. However, no common underlying mechanism was found. Finally, we conducted a systematic review (Study 3) aiming to elucidate factors contributing to the inconsistent results concerning the role of sex hormones in the two most addressed areas of emotional processing, emotion recognition (empathy-related measure) and emotional memory. Thereby, we extended previous reviews that address single areas of emotion processing. Moreover, we systematically addressed the role of situational features (mainly emotion-type and/or stimulus valence). All studies included healthy women of reproductive age either in stages of their natural menstrual cycle or using oral contraceptives, and measured or at least estimated levels of ovarian sex hormones. We document the methodological diversity in the field, presumably contributing to the heterogeneity of results. We recognized the need for studies explicitly contrasting the early follicular, mid-cycle, and mid-luteal phases, as well as OC-intake and using standardized tasks. Research would take advantage of using within-subject design more frequently and account for the recognition of complex emotions. In sum, our data suggest that sex hormones differentially modulate the cognitive and affective empathy-related performance and skin-conductance responses by interacting with situational variables, such as the emotional valence of the stimuli and the gender of the protagonist. Women in the luteal phase and under oral contraceptive use demonstrated better recognition of emotions depicted by female protagonists. By contrast, estradiol levels positively correlated with the recognition of emotions depicted by male protagonists. Sex-hormone status main effects only manifested in the emotion recognition advantage of free-cycling women over men (Reading the Mind in The Eyes Test; Study 2). In both studies, affective empathy ratings towards negative emotions were higher in the oral contraceptive users. Moreover, although mimic activity was not associated with sex hormones, skin-conductance responses to negative stimuli were heightened in the luteal phase. On the other hand, the performance in empathy-related measures in different hormone-status groups was not related to odor discrimination ability. Additionally, the inconsistencies of the sex hormone and emotion research could be the result of variations of designs and tasks used across studies from a similar field. This is also indicated in our findings from the empathy-related measures differing in tasks and hormone-status groups in two studies. Finally, our findings provide evidence that emotional processes under sex-hormone modulation are situated, i.e., subject to the influence of the stimulus valence. Furthermore, they are embodied via coupling between the endocrine system and the brain as evident in hormone status and valence interactions in empathy-related measures and sympathetic reactivity.

Das Ziel dieser Arbeit war zunächst in der Methodenoptimierung eines bereits grundlegend etablierten Protokolls zur Isolierung und Kultur equiner endometrialer Epithel (EEZ) und Stromazellen (ESZ) (BUSCHATZ 2007) zu sehen. Zudem wurde die Entwicklung weiterer Möglichkeiten des Handlings angestrebt (Passagierung, Kryokonservierung). So sollten den Zellen optimierte Rahmenbedingungen in vitro geboten werden, welche den Verhältnissen im Organismus weitgehend nahe kommen. Im Anschluss daran wurden die Zellen in vitro hinsichtlich ihrer morphologisch-funktionellen Charakteristika untersucht und die Befunde vergleichend zu den Gegebenheiten in situ betrachtet. Besonderes Augenmerk galt dabei der Expression von Progesteron- (PR) und Östrogenrezeptor-α (ERα) und von Inhibin-α. Wären vergleichbare Konstellationen in vitro und in vivo anzutreffen, könnte ein solches Kultursystem als Modell zum Studium interzellulärer Wechselwirkungen oder pathogenetischer Abläufe am Endometrium dienen. Voraussetzung hierfür wäre jedoch eine fortgeschrittene zelluläre Differenzierung, wie sie beispielsweise durch die Expression von Inhibin-α und der Steroidhormonrezeptoren angezeigt wird. Es wurden transzervikale Uterusbioptate und vollständige Uteri euthanasierter Stuten für die Zellaufreinigung sowie die vergleichende histologische Untersuchung gewonnen. Einer mechanischen und enzymatischen Dissoziation des Gewebes folgte die Separation beider Zellarten durch Filtration, Dichtegradientenzentrifugation und Differenzialadhärenz. Die Kultur erfolgte in wasserdampfgesättigter Raumluft bei 37 °C in 5 % CO2-Atmosphäre. Als Kulturmedium diente DMEM/Ham´s F-12 unter Zusatz von 2,5 % fötalem Kälberserums und diverser Additive. Es wurde eine morphologische Charakterisierung der Zellen während der Kultur vorgenommen und zudem ERα, PR und Inhibin-α an allen Kulturen und Gewebeproben immunhistologisch bestimmt. Das Ablösen der Zellen zur Passagierung erfolgte mit Trypsin-EDTA (ESZ) bzw. Alfazyme® (EEZ). Entsprechend abgelöste Zellen wurden zudem in DMSO-haltigem Nährmedium kryokonserviert. Die Kultivierung von EEZ und ESZ gelang sowohl bei Verwendung transzervikaler Uterusbioptate als auch bei Uteri euthanasierter Pferde. Zudem konnten alle physiologischerweise bei der Stute auftretenden Zyklusstände (Anöstrus, Interöstrus, Östrus) sowie ein gravider Uterus kultiviert werden. Die Konfluenz wird von EEZ nach 4 bis 16 d und von ESZ innerhalb von 7 bis 18 d erreicht, wobei Zellen aus ursprünglich proliferativen endometrialen Funktionszuständen tendenziell eher konfluent sind als sekretorisch aktive. Während der Kultur kann eine eindeutige morphologische Unterscheidung beider Zellarten voneinander erfolgen. ESZ besitzen eine spindelige, teils sternförmige, insgesamt „fibroblastenartige“ Gestalt. EEZ sind in zwei morphologischen Subtypen anzutreffen. Der monomorphe Zelltyp „A“ stellt kleine, polygonale Zellen mit regulären und regelmäßigen Zellgrenzen dar. Zelltyp „B“ ist größer, pleomorph, ebenfalls polygonal, mehrkernig und besitzt unregelmäßige, schlecht erkennbare Zellgrenzen. Subkultivierungen waren bis zu 20 (ESZ) bzw. 24 mal (EEZ) möglich. Zudem konnten beide Zellarten in flüssigem Stickstoff gelagert (kryokonserviert) und danach erfolgreich kultiviert werden. Weiterhin gelang der Nachweis von Inhibin-α im Uterus des Pferdes. Hierbei wurde eine zyklische Dynamik in der Expression festgestellt (stärkere Expression während der sekretorischen Phase), welche als Hinweis für eine sekretorische Differenzierung der EEZ anzusehen ist. Ebenfalls konnte dieses Protein in kultivierten EEZ und in viel geringerem Maße auch in den ESZ gefunden werden. Darüber hinaus war erstmalig der Nachweis von PR und ERα in beiden Zellarten in vitro möglich. Insgesamt ist die Expression dieser drei für uterines Gewebe essentiellen Rezeptoren/Proteine in kultivierten EEZ und ESZ als Hinweis für eine fortgeschrittene Differenzierung anzusehen, welche mit der vorgestellten Methode der Isolierung und Kultur auch erreicht werden konnte. Im Hinblick auf die Wachstumsgeschwindigkeit in vitro fanden sich zudem Hinweise auf eine Beibehaltung der ursprünglich im Gewebeverband erlangten zellulären Differenzierung, welche sich bei der Expression von ERα, PR bzw. Inhibin-α allerdings nicht nachvollziehen ließ. Abschließend betrachtet, deuten die vorliegenden Ergebnisse somit auf eine partielle Beibehaltung in situ erlangter endometrialer Funktionen und Spezifika hin, welche als Grundlage für weitere Arbeiten an endometrialen Zellkulturen des Pferdes anzusehen sind.